Biosimilar Antibodies:
Examining the Facts and the Clinical Dilemmas

18th Congress of the European Association of Hospital Pharmacists

AGENDA

14.00 Welcome and introduction

14.05 Biosimilar antibodies: Are we prepared?  
Jos Kosterink, PharmD, PhD

14.25 Q & A

Timothy Illidge, MD, PhD

14.50 Q & A

14.55 Case #2: Breast cancer: A critical appraisal of biosimilar anti-HER2 antibodies  
Javier Cortés, MD, PhD

15.15 Q & A

15.20 Take-home messages

Chair and Moderator
Jos Kosterink, PharmD, PhD  
University Medical Center Groningen  
Groningen, the Netherlands

Faculty
Timothy Illidge, MD, PhD  
The Christie Hospital  
Manchester, United Kingdom

Javier Cortés, MD, PhD  
Vall d’Hebron University Hospital  
Barcelona, Spain

Target Audience
This educational activity is specifically designed for pharmacists and other healthcare providers interested in biosimilar antibodies.

Learning Objectives
After successful completion of this educational activity, participants should be able to:

◆ Discuss the complexities regarding biosimilar antibody development and usage
◆ Evaluate the role of monoclonal antibodies in the treatment of lymphoma and breast cancer
◆ Analyze major issues of contention regarding biosimilar antibodies, including immunogenicity, extrapolation, traceability, and automatic substitution

This meeting is a prIME Oncology activity.

Support for this educational activity is provided by F. Hoffmann - La Roche Ltd.